Biofil Chemicals & Pharmaceuticals liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

2.79×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.73×	1.73×	1.34×	1.35×	1.63×
1.54×	1.54×	1.23×	1.26×	1.54×
0.1	0.1	0.1	0.1	0.0
15.2	15.2	10.7	9.9	8.7

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

BIOFILCHEM₹29.41

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersMANGALAM VINEETLAB LASA ORTINGLOBE KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹47.9 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	2.79
Current Ratio	1.63	1.35	1.34	1.73	1.73
Quick Ratio	1.54	1.26	1.23	1.54	1.54
Cash, Equiv & ST Investments	0.0	0.1	0.1	0.1	0.1
Working Capital	8.7	9.9	10.7	15.2	15.2

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.